Mallia Aesthetics Presents Data on the Role of sCD83 in Hair Growth at Third Barcelona Hair Meeting

Two oral presentations highlight the science behind 8T3 Essentials Hair Serum.

Erlangen, Germany, 14 September 2026 - Mallia Aesthetics GmbH, a company focusing on the development and commercialization of cosmetic products to stimulate hair growth, today announced its participation in the Third Barcelona Hair Meeting, which will take place September 17–19, 2026, in Sitges, Barcelona, Spain.

Co-founders of Mallia will deliver two oral presentations highlighting complementary research on sCD83, from its effects on human hair follicles ex vivo to results of a six-month user study with the 8T3 Essentials Hair Serum:

“Soluble CD83 Promotes Hair Growth in Human Hair Follicles Ex Vivo” (FC08) will be presented by Dr. Dmytro Royzman during Session 4 in Room Llevant.

Friday, September 18, from 11:00 to 11:50 a.m.

The ex vivo research findings demonstrate that sCD83 promotes hair shaft elongation and prolongs the growing phase of human hair follicles. Results further demonstrate effects regarding hair follicle stem cell activation and anti-inflammatory processes, providing new insights into how sCD83 supports hair growth at the follicular level.

“Efficacy and Safety of a sCD83-Based Hair Serum in Healthy Adult Male and Female Volunteers with Hair Loss” (FC33) will be delivered by Prof. Dr. Alexander Steinkasserer during Session 10 in Room Llevant.

Saturday, September 19, from 10:00 to 10:40 a.m.

In a six-month consumer study, 23 adult male and female participants experiencing hair loss used 8T3 Essentials Hair Serum twice weekly. The study showed an average increase of 20 hairs per square centimeter, corresponding to a 30% increase in hair density. User satisfaction was high: 95% reporting a reduction in hair loss, with 80% of users noticing new hair growth. No side effects were reported.

About sCD83

Soluble CD83 (sCD83) is an immunomodulatory protein currently being developed for the topical treatment of hair loss (MAL‑856) and stimulation of hair growth (MAL‑838). The soluble CD83 protein was first identified in 2001 by Prof. Steinkasserer, a co-founder of Mallia. It possesses anti-inflammatory properties by inducing resolution of inflammation, which promotes wound healing and induces new hair growth^[1]. In addition, sCD83 has been shown to activate regulatory T cells (Tregs)^[2], which can directly interact with and activate hair follicles.^[3] Furthermore, sCD83 inhibits cell death of hair follicle cells and directly activates follicular stem cells, as well as keratin production, thereby stimulating new hair growth. This multimodal mechanism distinguishes sCD83 from other topically applied hair growth products.

When topically applied, sCD83 directly enters the hair follicles but does not penetrate through the skin and thus does not enter the bloodstream. The effect is localized, which is a significant advantage over systemic treatment options, which can cause severe side effects.

About hair loss

Hormone-related hair loss in men and women (androgenetic alopecia, or AGA) is the most common form of hair loss. Worldwide, more than 70% of men and 50% of postmenopausal women are affected by androgenetic alopecia. An additional 147 million people suffer from immune-mediated, circular hair loss (alopecia areata, or AA^[4],[5]).

Androgenetic alopecia usually progresses gradually and is caused by genetic and hormonal factors. In men, it often leads to a receding hairline and baldness on the top of the head, while in women it leads to thinning hair along the part. Alopecia areata causes circular patches of hair loss on the scalp, face, or other parts of the body. It occurs when the immune system erroneously attacks hair follicles, leading to immune-mediated hair loss.

About Mallia

Mallia Innovations GmbH, based in Erlangen, Germany, is the holding company strategically driving the proprietary development and commercialization of biopharmaceutical therapies and cosmetic applications based on the immunomodulatory sCD83 protein. These are aimed at hair growth, hair loss, and other dermatological indications, including wound healing.

Mallia Therapeutics GmbH focuses on the clinical development of novel therapies for patients suffering from androgenetic alopecia or alopecia areata. The active ingredient, MAL-856 is based on the scientifically proven immunomodulatory mode of action of sCD83, which has been investigated for over 25 years by Mallia Co‑founder Prof. Dr. Alexander Steinkasserer.^[6]

Mallia Aesthetics GmbH focuses on cosmetic applications designed to stimulate hair growth, which are also based on the scientifically validated sCD83 protein. The company develops innovative cosmetic products based on MAL-838, which are marketed to professionals and consumers.

To purchase products from the 8T3 Essentials line, please visit our online shop: https://8t3.com/en/

For more information, visit www.mallia.com and follow us on LinkedIn, Instagram, and Facebook.

^[1] Royzman, D., Peckert-Maier, K., Stich, L., König, C., Wild, A. B., Tauchi, M., ... & Steinkasserer, A. (2022). Soluble CD83 improves and accelerates wound healing by the induction of pro-resolving macrophages. Frontiers in Immunology, 13, 1012647. DOI: 10.3389/fimmu.2022.1012647

^[2] Bock, F., Rössner, S., Onderka, J., Lechmann, M., Pallotta, M. T., Fallarino, F., ... & Zinser, E. (2013). Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival. The Journal of Immunology, 191(4), 1965-1975. DOI: 10.4049/jimmunol.1201531

^[3] Ali, N., Zirak, B., Rodriguez, R. S., Pauli, M. L., Truong, H. A., Lai, K., ... & Rosenblum, M. D. (2017). Regulatory T cells in skin facilitate epithelial stem cell differentiation. Cell, 169(6), 1119-1129. DOI: 10.1016/j.cell.2017.05.002

^[4] Feinstein, R. P. (2022). Androgenetic alopecia.: https://emedicine.medscape.com/article/1070167-overview

^[5] Mostaghimi, A., Gandhi, K., Done, N., Ray, M., Gao, W., Carley, C., ... & Sikirica, V. (2022). All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States. Journal of Managed Care & Specialty Pharmacy, 28(4), 426-434: DOI: 10.18553/jmcp.2022.28.4.426

^[6] Lechmann, M., Krooshoop, D. J., Dudziak, D., Kremmer, E., Kuhnt, C., Figdor, C. G., ... & Steinkasserer, A. (2001). The extracellular domain of CD83 inhibits dendritic cell–mediated T cell stimulation and binds to a ligand on dendritic cells. The Journal of experimental medicine, 194(12), 1813-1821. DOI: 10.1084/jem.194.12.1813